Logo

Bio-Thera Solutions Expands its Partnership with Pharmapark for BAT2306 (Biosimilar, Cosentyx) Across Russia and Other Countries

Share this

Bio-Thera Solutions Expands its Partnership with Pharmapark for BAT2306 (Biosimilar, Cosentyx) Across Russia and Other Countries

Shots:

  • Pharmapark will hold exclusive distribution, and marketing rights & filing for BAT2306 (Secukinumab bsm) which has finished the P-I & P-III study globally and plans to submit applications for approval to the NMPA, EMA & FDA.
  • Under the terms of the agreement, BAT2306 will be developed & supplied by Bio-Thera at its Guangzhou, China facility, and Pharmapark will be responsible for the regulatory & commercial activities across Russia and CIS countries
  • This is a third expansion of the existing agreement between the two companies which includes BAT2506 (Biosimilar, Golimumab) also includes BAT2206 (Biosimilar, Ustekinumab)

Ref: Bio-Thera Solutions and Pharmapark Image: Bio-Thera Solutions and Pharmapark

Related News:- Bio-Thera Solutions Reports an Initiation of P-III Clinical Trial of BAT2306, a Proposed Biosimilar of Cosentyx (secukinumab) for Plaque Psoriasis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com


Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions